Cover Image
市場調查報告書

甲狀腺癌症:開發中產品分析

Thyroid Cancer - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213074
出版日期 內容資訊 英文 490 Pages
訂單完成後即時交付
價格
Back to Top
甲狀腺癌症:開發中產品分析 Thyroid Cancer - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 490 Pages
簡介

甲狀腺癌症,是指在甲狀腺內部異常細胞開始發展的疾病。症狀脖子有腫的感覺,吞嚥困難,及頭和喉嚨的疼痛,頸部淋巴結腫大等。原因為女性,高層級的放射線,遺傳的症候群等。治療有手術和甲狀腺荷爾蒙治療。

本報告提供全球各國的甲狀腺癌症治療用的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將其結果為您概述為以下內容。

簡介

  • 分析範圍

甲狀腺癌症概要

治療藥的開發

  • 甲狀腺癌症開發中產品:概要

各企業開發中的甲狀腺癌症治療藥

大學/研究機關研究中的甲狀腺癌症治療藥

甲狀腺癌症治療藥:開發中的產品一覽(各企業)

甲狀腺癌症治療藥:研究中的產品一覽(大學/研究機關)

甲狀腺癌症:治療藥的評估

  • 各標的
  • 各行動機制
  • 各投藥法
  • 各分子類型

甲狀腺癌症開發治療藥的企業

  • AbbVie Inc
  • Advenchen Laboratories LLC
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd
  • Biovista Inc
  • Blueprint Medicines Corp
  • Boehringer Ingelheim GmbH
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cytori Therapeutics Inc
  • 第一三共
  • Ecrins Therapeutics SAS
  • Eisai
  • Ensol Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • Genelux Corp
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Gradalis Inc
  • Hutchison MediPharma Ltd
  • Ignyta Inc
  • Immune Pharmaceuticals Inc
  • Immunomedics Inc
  • Johnson & Johnson
  • Loxo Oncology Inc
  • MacroGenics Inc
  • MaxiVAX SA
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Nerviano Medical Sciences Srl
  • Novartis AG
  • 小野藥品
  • Pfizer Inc
  • Plexxikon Inc
  • Rodos BioTarget GmbH
  • Savoy Pharmaceuticals Inc
  • Synactix Pharmaceuticals Inc
  • Tarveda Therapeutics Inc
  • Vaccinex Inc
  • Vascular Biogenics Ltd

藥物簡介

甲狀腺癌症治療藥:開發暫停的產品

甲狀腺癌症治療藥:開發中止的產品

甲狀腺癌症相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9699IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer - Pipeline Review, H2 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.

Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 33, 28, 1, 11 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively.

Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Thyroid Cancer - Overview
  • Thyroid Cancer - Therapeutics Development
  • Thyroid Cancer - Therapeutics Assessment
  • Thyroid Cancer - Companies Involved in Therapeutics Development
  • Thyroid Cancer - Drug Profiles
  • Thyroid Cancer - Dormant Projects
  • Thyroid Cancer - Discontinued Products
  • Thyroid Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Thyroid Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Thyroid Cancer - Pipeline by AbbVie Inc, H2 2017
  • Thyroid Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
  • Thyroid Cancer - Pipeline by AstraZeneca Plc, H2 2017
  • Thyroid Cancer - Pipeline by Bayer AG, H2 2017
  • Thyroid Cancer - Pipeline by BeiGene Ltd, H2 2017
  • Thyroid Cancer - Pipeline by Biovista Inc, H2 2017
  • Thyroid Cancer - Pipeline by Blueprint Medicines Corp, H2 2017
  • Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Thyroid Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Thyroid Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
  • Thyroid Cancer - Pipeline by Centrose LLC, H2 2017
  • Thyroid Cancer - Pipeline by Curis Inc, H2 2017
  • Thyroid Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017
  • Thyroid Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H2 2017
  • Thyroid Cancer - Pipeline by Eisai Co Ltd, H2 2017
  • Thyroid Cancer - Pipeline by Ensol Biosciences Inc, H2 2017
  • Thyroid Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Thyroid Cancer - Pipeline by Genelux Corp, H2 2017
  • Thyroid Cancer - Pipeline by Genmab A/S, H2 2017
  • Thyroid Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Thyroid Cancer - Pipeline by Gradalis Inc, H2 2017
  • Thyroid Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017
  • Thyroid Cancer - Pipeline by Ignyta Inc, H2 2017
  • Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2017
  • Thyroid Cancer - Pipeline by Immunomedics Inc, H2 2017
  • Thyroid Cancer - Pipeline by Johnson & Johnson, H2 2017
  • Thyroid Cancer - Pipeline by Konruns Pharmaceutical Co Ltd, H2 2017
  • Thyroid Cancer - Pipeline by Loxo Oncology Inc, H2 2017
  • Thyroid Cancer - Pipeline by MacroGenics Inc, H2 2017
  • Thyroid Cancer - Pipeline by MaxiVAX SA, H2 2017
  • Thyroid Cancer - Pipeline by MedImmune LLC, H2 2017
  • Thyroid Cancer - Pipeline by Merck & Co Inc, H2 2017
  • Thyroid Cancer - Pipeline by Merck KGaA, H2 2017
  • Thyroid Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Thyroid Cancer - Pipeline by Nerviano Medical Sciences Srl, H2 2017
  • Thyroid Cancer - Pipeline by Novartis AG, H2 2017
  • Thyroid Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • Thyroid Cancer - Pipeline by Pfizer Inc, H2 2017
  • Thyroid Cancer - Pipeline by Plexxikon Inc, H2 2017
  • Thyroid Cancer - Pipeline by Rodos BioTarget GmbH, H2 2017
  • Thyroid Cancer - Pipeline by Synactix Pharmaceuticals Inc, H2 2017
  • Thyroid Cancer - Pipeline by Tarveda Therapeutics Inc, H2 2017
  • Thyroid Cancer - Pipeline by Vaccinex Inc, H2 2017
  • Thyroid Cancer - Pipeline by Vascular Biogenics Ltd, H2 2017
  • Thyroid Cancer - Pipeline by XSpray Microparticles AB, H2 2017
  • Thyroid Cancer - Dormant Projects, H2 2017
  • Thyroid Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Thyroid Cancer - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Thyroid Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top